In Vivo Evaluation of 11C-labeled Three Radioligands for Glycine Transporter 1 in the Mouse Brain
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective: Glycine transporter 1 (GlyT-1) is one of the most attractive therapeutic targets for schizophrenia. There is great interest in developing radioligands for in vivo imaging of GlyT-1 in the brain using positron emission tomography. Here, we report the properties of three novel non-sarcosine-based radioligands [11C]CHIBA-3007, [11C]CHIBA-3009, and [11C]CHIBA-3011, for GlyT-1imaging in the mouse brain in vivo. Methods: The three radioligands were synthesized by N-[11C] methylation of the corresponding desmethyl precursor. A pharmacological characterization of these radioligands for in vivo imaging of GlyT-1 in the brain was conducted using male ddY mice. Results: [11C]CHIBA-3009 and [11C]CHIBA-3011 were scarcely incorporated into the brain, whereas [11C]CHIBA-3007 showed slight but considerable brain uptake. Regional brain uptake of [11C]CHIBA-3007 (medulla oblongata＞cerebellum＞cortex) was similar to the distribution of the GlyT-1 protein. However, pretreatment with CHIBA-3007 (1 mg/kg) or the GlyT-1 selective inhibitor ALX5407 (N-[(3R)-3-([1,1'-Biphenyl]-4-yloxy)-3-(4-fluorophenyl)propyl]-N-methylglycine) (30 mg/kg) did not significantly decrease brain uptake of [11C]CHIBA-3007, suggesting low specific binding to GlyT-1. Pretreatment with cyclosporin A significantly increased brain uptake of [11C]CHIBA-3009 and [11C]CHIBA-3011, suggesting a role for P-glycoprotein in the brain uptake of these ligands. All three radioligands were rapidly degraded intact forms were 3-18% in plasma and 15-74% in the brain at 15min after injection. Conclusion: The results suggest that these three radioligands are not suitable for in vivo imaging of GlyT-1 in the brain because of low brain uptake and rapid metabolism. Further structural refinement is necessary to enhance brain uptake.
Abstract
Objective: Glycine transporter 1 (GlyT-1) is one of the most attractive therapeutic targets for schizophrenia. There is great interest in developing radioligands for in vivo imaging of GlyT-1 in the brain using positron emission tomography. Here, we report the properties of three novel non-sarcosine-based radioligands [11C]CHIBA-3007, [11C]CHIBA-3009, and [11C]CHIBA-3011, for GlyT-1imaging in the mouse brain in vivo. Methods: The three radioligands were synthesized by N-[11C] methylation of the corresponding desmethyl precursor. A pharmacological characterization of these radioligands for in vivo imaging of GlyT-1 in the brain was conducted using male ddY mice. Results: [11C]CHIBA-3009 and [11C]CHIBA-3011 were scarcely incorporated into the brain, whereas [11C]CHIBA-3007 showed slight but considerable brain uptake. Regional brain uptake of [11C]CHIBA-3007 (medulla oblongata＞cerebellum＞cortex) was similar to the distribution of the GlyT-1 protein. However, pretreatment with CHIBA-3007 (1 mg/kg) or the GlyT-1 selective inhibitor ALX5407 (N-[(3R)-3-([1,1'-Biphenyl]-4-yloxy)-3-(4-fluorophenyl)propyl]-N-methylglycine) (30 mg/kg) did not significantly decrease brain uptake of [11C]CHIBA-3007, suggesting low specific binding to GlyT-1. Pretreatment with cyclosporin A significantly increased brain uptake of [11C]CHIBA-3009 and [11C]CHIBA-3011, suggesting a role for P-glycoprotein in the brain uptake of these ligands. All three radioligands were rapidly degraded intact forms were 3-18% in plasma and 15-74% in the brain at 15min after injection. Conclusion: The results suggest that these three radioligands are not suitable for in vivo imaging of GlyT-1 in the brain because of low brain uptake and rapid metabolism. Further structural refinement is necessary to enhance brain uptake.
참고문헌 (34)
- Javitt DC, "Recent advances in the phencyclidine model of schizophrenia", Am J Psychiatry, 148, pp.1301~1308 (1991)
- Olney JW, "Glutamate receptor dysfunction and schizophrenia", Arch Gen Psychiatry, 52, pp.998~1007 (1995)
- Hashimoto K, "Decreased serum levels of Dserine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia", Arch Gen Psychiatry, 60, pp.572~576 (2003)
- Hashimoto K, "Glutamate hypothesis of schizophrenia and approach for possible therapeutic drugs", Curr Med Chem Cent Nerv Syst Agents, 4, pp.147~154 (2004)
- Hashimoto K, "Dysfunction of glia-neuron communication in pathophysiology of schizophrenia", Curr Psychiatry Rev, 1, pp.151~163 (2005)
- Kenji Hashimoto, "The NMDA Receptor Hypofunction Hypothesis for Schizophrenia and Glycine Modulatory Sites on the NMDA Receptors as Potential Therapeutic Drugs", Clinical Psychopharmacology and Neuroscience, 4(1), pp.3~10 (2006), 대한정신약물학회
- Bergeron R, "Modulation of N-methyl-D-aspartate receptor function by glycine transport", Proc Natl Acad Sci USA, 95, pp.15730~15734 (1998)
- Johnson JW, "Glycine potentiates the NMDA response in cultured mouse brain neurons", Nature, 325, pp.529~531 (1987)
- Zafra F, "Molecular biology of glycinergic neurotransmission", Mol Neurobiol, 14, pp.117~142 (1997)
- Aragó:n C, "Glycine transporters: crucial roles of pharmacological interest revealed by gene deletion", Trends Pharmacol Sci, 26, pp.283~286 (2005)
- Eulenburg V, "Glycine transporters: essential regulators of neurotransmission", Trends Biochem Sci, 30, pp.325~333 (2005)
- Hashimoto K, "Glycine transporter inhibitors as therapeutic agents for schizophrenia", Recent Pat CNS Drug Discov, 1, pp.43~53 (2006)
- Smith KE, "Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors", Neuron, 8, pp.927~935 (1992)
- Cubelos B, "Localization of the GLYT1 glycine transporter at glutamatergic synapses in the rat brain", Cereb Cortex, 15, pp.448~459 (2005)
- CMPyPB glycine transporter 1 positron emission tomography radiotracers, "Synapse", 2011, 261~270
- Hashimoto K, "Glycine transporter-1 inhibitors as novel therapeutic drugs for schizophrenia", Cent Nerv Syst Med Chem, 7, pp.177~182 (2007)
- Hashimoto K, "Glycine transport inhibitors for the treatment of schizophrenia", Open Med Chem J, 4, pp.10~19 (2010)
- Hashimoto K, "Glycine transporter-1: a new potential therapeutic target for schizophrenia", Curr Pharm Des, 17, pp.112~120 (2011)
- Hashimoto K, "Phencyclidine- induced cognitive deficits in mice are improved by subsequent subchronic administration of the glycine transporter- 1 inhibitor NFPS and D-serine", Eur Neuropsychopharmacol, 18, pp.414~421 (2008)
- GSK931145 as a novel ligand for imaging the type 1 glycine transporter with positron emission tomography, "Synapse", 2010, 542~549
- 김종훈, "Biodistribution and Radiation Dosimetry of the Glycine Transporter-1 Ligand C-11-GSK931145 Determined from Primate and Human Whole-Body PET", MOLECULAR IMAGING AND BIOLOGY, 13(4), pp.776~784, SPRINGER
- Toyohara J, "In vivo evaluation of carbon-11-labelled non-sarcosine-based glycine transporter 1 inhibitors in mice and conscious monkeys", Nucl Med Biol, 38, pp.517~527 (2011)
- CHIBA-3007 binding to glycine transporter 1 in the rat brain, "PLoS One", 2011, e21322~
- Sekiguchi Y, "Glycine transporter inhibitor", International Patent Application WO, 01, pp.8639~ (2008)
- benzamide, preparation method thereof and application of same in therapeutics, "International Patent Application WO", 2005
- pyrrole series of inhibitors of the type 1 glycine transporter, "Bioorg Med Chem Lett", 2010, 907~911
- methyl triflate, "Ann Nucl Med", 2004, 165~168
- Borowsky B, "Two glycine transporter variants with distinct localization in the CNS and peripheral tissues are encoded by a common gene", Neuron, 10, pp.851~863 (1993)
- Zafra F, "Glycine transporters are differentially expressed among CNS cells", J Neurosci, 15, pp.3952~3969 (1995)
- McDevitt CA, "How can we best use structural information on P-glycoprotein to design inhibitors?", Pharmacol Ther, 113, pp.429~441 (2007)
- SA4503, by P-glycoprotein modulation, "Synapse", 2003, 80~86
- Elsinga PH, "PET Studies on P-glycoprotein function in the bloodbrain barrier: how it affects uptake and binding of drugs within the CNS", Curr Pharm Des, 10, pp.1493~1503 (2004)
- Ishiwata K, "In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically", J Nucl Med, 48, pp.81~87 (2007)
- Nojiri Y, "Radiosynthesis and biodistribution in mice of a 18F-labeled analog of O-1302 for use in cerebral CB1 cannabinoid receptor imaging", Biol Pharm Bull, 31, pp.1274~1278 (2008)